Nanocrystals, compositions, and methods that aid particle transport in mucus
Nanocrystals, compositions, and methods that aid particle transport in mucus are provided. In some embodiments, the compositions and methods involve making mucus-penetrating particles (MPP) without any polymeric carriers, or with minimal use of polymeric carriers. The compositions and methods may include, in some embodiments, modifying the surface coatings of particles formed of pharmaceutical agents that have a low water solubility. Such methods and compositions can be used to achieve efficient transport of particles of pharmaceutical agents though mucus barriers in the body for a wide spectrum of applications, including drug delivery, imaging, and diagnostic applications. In certain embodiments, a pharmaceutical composition including such particles is well-suited for administration routes involving the particles passing through a mucosal barrier.
1. A pharmaceutical composition for topical administration to an eye, the pharmaceutical composition comprising:
(a) a plurality of coated nanoparticles, wherein each coated nanoparticles comprises:
(i) a particle core comprising one or more solid pharmaceutical agents or salts thereof, wherein the one or more solid pharmaceutical agents or salts thereof constitutes at least 80% of the particle core by weight; and
(ii) a coating comprising a surface-altering agent surrounding the particle core, wherein the surface-altering agent comprises a triblock copolymer comprising a hydrophilic block-hydrophobic block-hydrophilic block configuration, wherein the hydrophobic block has a molecular weight of at least 2 kDa, and the hydrophilic blocks constitute at least 15 wt % of the triblock copolymer; and
(b) one or more pharmaceutically acceptable excipients;
wherein the coated nanoparticles diffuse through mucus at a greater rate than a control nanoparticle.
2. The pharmaceutical composition of claim 1 , wherein the control nanoparticle is a mucoadhesive particle.
3. The pharmaceutical composition of claim 2 , wherein the control nanoparticle is a 200 nm carboxylated polystyrene particle.
4. The pharmaceutical composition of claim 1 , wherein the control nanoparticle is a particle comprising a pharmaceutical agent or salt thereof non-covalently coated with sodium dodecyl sulfate.
5. The pharmaceutical composition of claim 1 , wherein the surface-altering agent is present on the surfaces of the coated nanoparticles at a density of at least 0.01 molecules per nanometer squared.
6. The pharmaceutical composition of claim 5 , wherein the one or more solid pharmaceutical agents or salts thereof constitutes at least 90% of the particle core by weight.
7. The pharmaceutical composition of claim 5 , wherein the particle core comprises a crystalline pharmaceutical agent or a salt thereof.
8. The pharmaceutical composition of claim 5 , wherein the surface-altering agent is covalently attached to the particle core.
9. The pharmaceutical composition of claim 5 , wherein the surface-altering agent is non-covalently adsorbed to the particle core.
10. The pharmaceutical composition of claim 5 , wherein the hydrophilic blocks of the triblock copolymer constitute at least 30 wt % of the triblock copolymer.
11. The pharmaceutical composition of claim 10 , wherein the hydrophobic block portion of the triblock copolymer has a molecular weight of at least 3 kDa.
12. The pharmaceutical composition of claim 11 , wherein the triblock copolymer is poly(ethylene oxide)-polypropylene oxide)-poly(ethylene oxide) or poly(ethylene glycol)-poly(propylene oxide)-poly(ethylene glycol).
13. The pharmaceutical composition of claim 10 , wherein the hydrophilic block of the triblock copolymer comprises poly(ethylene oxide) or poly(ethylene glycol) or a derivative thereof.
14. The pharmaceutical composition of claim 13 , wherein the poly(ethylene oxide) or poly(ethylene glycol) block has a molecular weight of at least 2 kDa.
15. The pharmaceutical composition of claim 5 , wherein the hydrophobic block of the triblock copolymer is poly(propylene oxide).
16. The pharmaceutical composition of claim 15 , wherein the poly(propylene oxide) block has a molecular weight of at least 3 kDa.
17. The pharmaceutical composition of claim 5 , wherein the surface-altering agent is present in the composition at a concentration of at least 0.1% (w/v).
18. The pharmaceutical composition of claim 5 , wherein the coated nanoparticles have an average size of at least 20 nm and less than or equal to 1 μm.
19. The pharmaceutical composition of claim 18 , wherein the average size is determined by dynamic light scattering.
20. The pharmaceutical composition of claim 5 , wherein the size polydispersity index of the coated particles is less than or equal to about 0.3.
21. The pharmaceutical composition of claim 20 , wherein the size polydispersity index is measured by dynamic light scattering.
22. The pharmaceutical composition of claim 5 , wherein the coated nanoparticles diffuse through human cervicovaginal mucus at a diffusivity that is greater than 1/500 the diffusivity that the particles diffuse through water on a time scale of 1 second.